Haematology 2018

Evolving Standards of Care in Non-Hodgkin’s Lymphoma clinicaloptions.com/oncology Guideline Recommendations for Treatment of Relapsed DLBCL ▪ Second-line therapy in candidates for high-dose therapy + ASCT ▪ Second-line therapy for patients who are not candidates for high-dose therapy

– DHAP ± rituximab – ESHAP ± rituximab – GDP ± rituximab – GemOx ± rituximab – ICE ± rituximab – MINE ± rituximab

– Clinical trial

– Rituximab

– CEPP ± rituximab

– Lenalidomide

– EPOCH ± rituximab

NCCN practice guidelines in oncology: non-Hodgkin’s lymphomas V.1.2010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf.